The Claim

Insulin-like growth factor binding protein 1 interacts with integrin β1 in mouse and human liver cells to reduce lipid accumulation.

Source: Insulin‐like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
39score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

In liver cells from mice and humans, insulin-like growth factor binding protein 1 binds to integrin β1 and reduces the buildup of lipids.

See the scientific wording

In mouse and human liver cells, insulin-like growth factor binding protein 1 interacts with integrin β1 (ITGB1) to reduce lipid accumulation, suggesting a potential molecular mechanism for its effects on fatty liver.

Why this might work

A protein called IGFBP1 attaches to a receptor on liver cells called ITGB1, which turns off genes that make fat and turns on genes that burn fat, leading to less fat buildup in the liver.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Insulin‐like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease

    Scientists found that when they added IGFBP1 to liver cells with too much fat, it stuck to another protein called ITGB1 and helped clear the fat away — in both mouse and human cells. This shows how IGFBP1 might work to fight fatty liver disease.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.